ISO 10993-1 2026 Updates: A Proactive Guide for Device Manufacturers

The upcoming revision of ISO 10993-1, the foundational standard for the biological evaluation of medical devices, represents a significant evolution in regulatory expectations. Anticipated around 2025-2026, these updates will continue the shift away from a simple checklist of biocompatibility tests and toward a more holistic, risk-based biological evaluation process. For medical device manufacturers, this change requires a proactive and fundamental adjustment to their strategies, integrating biological risk assessment from the earliest stages of device design to ensure continued compliance and prevent costly submission delays. Successfully navigating this new landscape means moving beyond asking "What tests do we need to run?" to "What is the overall biological risk of our device, and how can we best characterize and mitigate it?" This proactive approach emphasizes a deep understanding of device materials, manufacturing processes, and the specific clinical use. It elevates the importance of chemical characterization and toxicological risk assessment, often positioning them as primary tools to justify the omission of traditional, and often lengthy, in vivo animal studies. ## Key Points * **Shift from Testing to Risk Management:** The updated standard will further cement the move from a prescriptive testing checklist to a comprehensive biological risk assessment process. The Biological Evaluation Plan (BEP) is a living document that must justify the entire evaluation strategy. * **Chemical Characterization is Foundational:** Expect an increased emphasis on analytical chemistry (extractables and leachables) as a primary method for evaluating biocompatibility. A robust chemical characterization is no longer optional but a central pillar of the biological evaluation. * **Toxicological Risk Assessment (TRA) is Critical:** The ability to use chemical data to clear a device relies on a rigorous TRA. This assessment evaluates the health risks posed by identified chemical compounds and is essential for justifying a reduction in animal testing. * **Proactive Planning is Essential:** Biological evaluation can no longer be an end-of-design activity. It must be integrated into the product development lifecycle, influencing material selection and manufacturing processes from the start. * **Legacy Devices Require a Gap Analysis:** Manufacturers cannot assume that existing biocompatibility data for legacy devices will be sufficient. A formal gap analysis against the new standard's principles is necessary to identify and address potential deficiencies. * **FDA Engagement is Key for Novel Approaches:** For new materials, complex devices, or strategies that rely heavily on analytical data to replace in vivo tests, early engagement with the FDA through the Q-Submission program is a critical de-risking step. ## The Paradigm Shift: From Biocompatibility Testing to Biological Risk Assessment The core philosophy of the evolving ISO 10993-1 standard is that biological safety is not just proven by a series of passed tests but by a well-reasoned, scientifically-sound risk assessment. The goal is to understand and control potential biological risks throughout the device lifecycle. This risk-based approach requires manufacturers to think like detectives, gathering evidence from multiple sources to build a case for safety. This evidence includes: * **Physical and Chemical Information:** Deep knowledge of all device materials and their properties. * **Manufacturing Information:** Understanding how processes like sterilization, machining, or coating could introduce or alter chemicals. * **Pre-Clinical and Clinical Data:** Leveraging existing literature, historical device data, and any human use data. * **In Vitro and In Vivo Testing:** Using targeted laboratory tests to fill specific knowledge gaps identified during the risk assessment, not as a default starting point. The Biological Evaluation Plan (BEP) becomes the central document that outlines this entire investigative process, while the Biological Evaluation Report (BER) presents the findings and the final conclusion of safety. ## Evolving the Biological Evaluation Plan (BEP) A modern BEP that aligns with the upcoming standard must be more than a list of proposed tests. It is a comprehensive strategic document that details the "what, why, and how" of the entire evaluation. ### Key Components of a Proactive BEP: 1. **Device and Material Characterization:** * **Full Bill of Materials:** Identify every single material with patient contact, including colorants, adhesives, and processing aids. * **Material History and Supplier Data:** Document the history of safe use for each material in similar medical device applications. * **Manufacturing Impact Assessment:** Analyze how processes (e.g., sterilization, polishing, curing) could alter materials or introduce contaminants. 2. **Categorization and Endpoint Identification:** * **Device Categorization:** Formally categorize the device based on the nature and duration of body contact as defined in ISO 10993-1. * **Endpoint Identification:** Based on the categorization, identify all potential biological risks (e.g., cytotoxicity, sensitization, systemic toxicity) that need to be evaluated. This is the starting point for the risk assessment. 3. **Information Gathering and Gap Analysis:** * **Literature Review:** Conduct a thorough search for data on the device materials and any similar, legally marketed devices. * **Existing Data Assessment:** Analyze any existing biocompatibility or chemical data available for the device or its components. * **Identify the Gaps:** The crucial step is to determine which biological endpoints are not adequately addressed by existing information. This analysis dictates the testing strategy. 4. **Testing Rationale and Strategy:** * **Justification for Testing:** For every proposed test, the BEP must explain *why* it is necessary to address a specific risk identified in the gap analysis. * **Justification for *Not* Testing:** Equally important, the BEP must provide a strong scientific rationale for any endpoints that will *not* be evaluated through new testing (e.g., based on robust chemical characterization and toxicological risk assessment). ## The Central Role of Chemical Characterization and Toxicological Risk Assessment (TRA) Under the evolving standard, chemical characterization is the engine of the biological evaluation. Instead of implanting a device in an animal to see what happens, the goal is to first determine what chemicals could potentially be released from the device and then assess the toxicological risk of those specific chemicals. ### Step 1: Chemical Characterization (Extractables & Leachables) This process involves using aggressive solvents and analytical techniques to identify and quantify the chemical compounds that could be released from a device. * **Extractables:** A "worst-case" study to see what chemicals *can* be forced out of the device materials under laboratory conditions. * **Leachables:** A study under conditions that simulate clinical use to see what chemicals are *actually* released during the device's intended life. ### Step 2: Toxicological Risk Assessment (TRA) Once the chemical profile is known, a qualified toxicologist assesses the potential health risk. * **Hazard Identification:** The toxicologist identifies the potential adverse health effects associated with each identified chemical. * **Dose-Response Assessment:** They determine the relationship between the dose of a chemical and the incidence of adverse effects. * **Exposure Assessment:** They calculate the maximum amount of each chemical a patient could be exposed to from the device. * **Risk Characterization:** The final step compares the predicted patient exposure to the safe exposure level (Tolerable Intake or TI). If the patient exposure is well below the safe level, the risk is considered acceptable. A well-executed TRA can provide a powerful justification for concluding that certain biological endpoints have been adequately addressed without needing new in vivo tests. ## Addressing Legacy Devices: A Gap Analysis Framework Manufacturers must not assume that devices with a long history of safe use are exempt from scrutiny under the updated standard. A formal gap analysis is required to demonstrate that the existing data meets modern expectations. ### A Step-by-Step Gap Analysis Process: 1. **Re-evaluate Device Categorization:** Confirm the device's body contact nature and duration are correctly documented according to the latest version of the standard. 2. **Review the Original Evaluation:** Compile all historical biocompatibility test reports and supporting data. 3. **Compare Against Current Endpoints:** Create a table comparing the endpoints evaluated in the historical data against all endpoints required by the current/upcoming standard for that device category. 4. **Scrutinize Historical Test Methods:** Verify that old tests were conducted at GLP-compliant labs and that the methods are still considered valid. For example, older cytotoxicity or sensitization tests may not meet current standards. 5. **Assess Material and Manufacturing Changes:** Document every change, no matter how small, to materials, suppliers, or manufacturing processes since the original testing was performed. Each change requires a risk assessment. 6. **Develop a Justification or Remediation Plan:** * If gaps are identified, the plan may involve new testing (e.g., a targeted chemical characterization and TRA). * Alternatively, it may involve writing a detailed scientific justification explaining why the existing data is sufficient to address the identified risk. This is often where a TRA based on existing literature can be used. Re-testing or a new TRA would be warranted if there has been a change in materials or manufacturing, if the original testing is incomplete by modern standards, or if new information about a material's toxicity has become available. ## Strategic Considerations and the Role of Q-Submission For any device—new or legacy—where the biological evaluation strategy deviates from a simple testing checklist, proactive communication with regulators is crucial. This is especially true when relying heavily on chemical characterization and a TRA to waive in vivo testing for a long-term implantable device. The FDA's Q-Submission program is the ideal mechanism for this. A Pre-Submission (Pre-Sub) allows a manufacturer to present its proposed Biological Evaluation Plan (BEP) to the FDA and receive feedback *before* committing to expensive and time-consuming studies. A Q-Sub for biocompatibility is most valuable when: * Introducing a novel material with limited history of use. * Justifying the absence of long-term animal testing for an implantable device based on analytical and toxicological data. * Seeking agreement on a gap analysis and remediation plan for a legacy device. * The device has a complex risk profile due to its materials, design, or clinical use. Presenting a well-developed BEP and a preliminary risk assessment to the FDA demonstrates a thorough, proactive approach and can significantly de-risk the final 510(k) or De Novo submission. ## Finding and Comparing Biocompatibility Testing Services Providers Choosing the right testing partner is critical for successfully navigating the updated ISO 10993-1 requirements. A qualified provider is more than just a testing lab; they are a strategic partner who can help develop and execute a sound biological evaluation strategy. When evaluating providers, look for: * **Deep Expertise in ISO 10993:** They should have a team of experts, including toxicologists and chemists, who understand the nuances of the standard and regulatory expectations. * **Advanced Chemical Characterization Capabilities:** Ensure they have a state-of-the-art analytical chemistry lab and experience performing rigorous extractables and leachables studies compliant with ISO 10993-18. * **In-House Toxicology Support:** The ability to perform a Toxicological Risk Assessment (TRA) is essential. A partner with in-house, board-certified toxicologists can provide a seamless transition from chemical data to risk analysis. * **Regulatory Experience:** The provider should have a strong track record of submitting biocompatibility data to global regulatory bodies, including the FDA, and understand how to present data effectively. * **Strategic Guidance:** The best partners act as consultants. They can help you design a smart BEP, conduct a thorough gap analysis, and provide justifications that will stand up to regulatory scrutiny. Comparing providers based on their strategic capabilities, not just their price list for individual tests, is key to a successful and cost-effective biological evaluation. > To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/biocompatibility_testing) and request quotes for free. ## Key FDA References When developing a biological evaluation strategy for the US market, it is essential to consult the FDA's current thinking. Key documents generally include: * **FDA Guidance: Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process"**: This is the primary guidance outlining the FDA's expectations for biocompatibility. * **FDA's Q-Submission Program Guidance**: This document details the process for requesting feedback from the FDA on regulatory strategies, including biocompatibility plans. * **Relevant sections of 21 CFR**: Regulations governing medical devices, such as those under 21 CFR Part 807 for premarket notification, establish the framework into which biocompatibility data must fit. Sponsors should always refer to the FDA's website for the most current versions of these and other relevant guidance documents. *** *This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program.* --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*